CHARITY REGISTRATION NUMBER: 1205000
COMPANY REGISTRATION NUMBER: CE033752

Axial Spondyloarthritis International Federation

Report and Accounts

31 December 2025

GORDON & CO
Chartered Accountants and Business Advisors
4 Bloomsbury Square
London
WC1A 2RP

Axial Spondyloarthritis International Federation

Contents

Year ended 31 December 2025

	Page
Reference and administrative details	**1**
Trustees' annual report	**2**
Independent examiner’s report to the Trustees	**7**
Statement of financial activities	**8**
Statement of financial position	**9**
Notes to the accounts	**10**

Axial Spondyloarthritis International Federation
Reference and Administrative Details

Year ended 31 December 2025

Reference and administrative details

Registered charity name	Axial Spondyloarthritis International Federation	
Charity registration number	1205000	
Company registration number	CE033752	
Registered office	27 Old Gloucester Street London WC1N 3AX	
The Trustees	Zhivko Yankov - Chair	
	René Bräm - Treasurer	From 1 February 2025
	Lillann Wermskog – Vice- Chair	
	Andri Phoka	Secretary to October 2025
	Nadia Malliou	Secretary from October 2025
	Dr Tuncay Duruöz	
	Cassie Shafer	
	Prachee Bhosle	
	Julieth Buitrago	
	Geraldine M Bonites	From October 2025
	Simon Grosswiler	From October 2025
Staff and volunteers	Jo Davies	Director of Operations
	Jo Lowe	Project Manager
	Joanne de Bry	Communications Manager
Advisor	Fiona Kerin FCA	Accountant
Bankers	HSBC UK Bank PLC 15 Wellington Street Woolwich London SE18 6PH	CAF Bank 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ
Independent examiner	John Gordon FCA Gordon & Co 4 Bloomsbury Square London WC1A 2RP	

Axial Spondyloarthritis International Federation
Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation

Year ended 31 December 2025

The Trustees present their report and the accounts of the charity for the year ended 31 December 2025.

Axial Spondyloarthritis International Federation ("ASIF") has been in existence as a charity since 1988. Following approval from the members at an AGM in 2022, the charity was registered as a Charitable Incorporated Organisation (CIO) on 2 October 2023.

Structure, governance and management

Constitution
ASIF is a charitable incorporated organisation (CIO), formed in 1988, comprising a world network of societies and associations representing patients suffering from Axial Spondyloarthritis ("axSpA"). These societies and associations are members of ASIF.

ASIF's constitution includes the requirement that a general meeting of all members of ASIF must be held annually, at which Trustees are elected to manage the affairs of the association.

The CIO constitution allows that Trustees can be either a nominated representative of a member organisation or other persons who are elected on the basis of relevant skills and experience that they will bring to the charity trustee board.

The constitution requires that there are a minimum of five Trustees and a maximum of twelve Trustees. Trustees are normally appointed for a term of three years and a maximum of three terms.

Management
ASIF is overseen by the Trustees, who meet at least four times a year. Working with the staff team, the Trustees determine ASIF policies, decide on the strategic direction of ASIF and review existing funds and set budgets for future expenditure. Decisions are made by a simple majority vote.

Trustees are entitled to claim reimbursement of expenses.

The staff team are led by the Director of Operations who works closely with the Chair and the Trustees to determine the strategic direction of the charity and with the staff team to operational the strategic plan.

Risk assessment
The Trustees have reviewed the risks faced by ASIF and have adopted appropriate policies to mitigate these risks. These risks are reviewed periodically by the Trustees. The Trustees believe that ASIF has sufficient resources for the time being to support its activities.

Objectives and activities

ASIF's mission is *A world where everyone affected by axSpA lives their best life.*
The Object of the Charity is:

"The relief of sickness and preservation of health by advancing the diagnosis and treatment of persons suffering from, Axial Spondyloarthritis and its related conditions throughout the world through promoting awareness and funding and encouraging research into, the causes, diagnosis and effective treatments of Axial Spondyloarthritis and its related conditions throughout the world and disseminating the results of such research worldwide."

ASIF seeks to achieve this objective through organising conferences for member organisations, running global projects and disseminating information to members, public and stakeholders, and through making presentations to and working with affiliated groups including representatives of the pharmaceutical industry.

Achievements and performance

In 2025 ASIF continued to develop its major projects:

World AS Day

WAS Day remains ASIF's main annual global awareness campaign. In 2025 WAS Day was on 3 May, however the campaign runs throughout April and May. The social media campaign reached an incredible 23.7 million people worldwide and the video play were up 264% on the previous year at 6.2 million. The campaign tools were made available, ready to use, to our members, with the ability for them easily to translate the language and add their own organisational branding.

The 2025 theme was 'Lace Up For axSpA' which highlighted everyday challenges faced by people living with axSpA. We awarded seven social media grants to members to boost their campaigns and send traffic to their own website pages.

Many members and industry partners held events including webinars. The Spondylitis Association of America ran the annual Global Spondyloarthritis Summit which provides insightful presentations for people affected by axSpA. Walk Your AS Off, a global virtual awareness and fundraising walk continues to create some keen competition around the world.

LAMAS

Following on from the success of IMAS, the International Map of Axial Spondyloarthritis coupled with the success of the Latin American regional meeting held in Bogotá in October 2024, it was decided that ASIF would produce a regional report focussed on the IMAS data collected in Latin America called the Latin American Map of Axial Spondyloarthritis. A working group was created with patients and HCPs from the region and statistical analysis provided by Marco Garrido Cumbrera of the University of Seville. This work continued throughout 2025, the report will be launched at PANLAR in April 2026.

IMAS/IMAP

The International Map of Axial Spondyloarthritis (IMAS) was a comprehensive online patient survey of individuals living with axSpA; it assessed the impact and burden of the disease from the patient perspective and on healthcare utilisation. In 2024, Novartis, who funded IMAS, transferred the assets to ASIF. During 2025, trustees and staff considered what, if anything, should be done with

IMAS. Members, trustees and scientific advisors were consulted and allagreed that the survey should be run again. Now fully owned by ASIF, the upcoming study will address new relevant aspects of both axial spondyloarthritis and psoriatic arthritis (PsA), incorporate perspectives from a broader range of countries, and provide new essential data for patient organisations, researchers, clinicians and other stakeholders. Towards the end of 2025, a concept note for the new project the International Map of axSpA and PsA (IMAP), was drafted and research funding sought. ASIF was successful in securing the first funder for this study, Alfasigma, at the end of 2025. The project will launch early in 2026, focussing initially on Europe, whilst further funding is sought to take IMAP to the rest of the world.

Expert Advisory Committee

In March 2025 the first meeting of the newly formed Expert Advisory Committee was held. Members of that committee are listed on the ASIF website. Members include representatives from rheumatology, physiotherapy, psychology, nursing, academic research, epidemiology and patient representatives. Their remit is to advise on the framing, design and delivery of ASIF's work from the perspective of healthcare professionals, to serve as a forum to discuss potential areas of collaboration between patient organisations and professional healthcare sectors and to support ASIF in building partnerships.

Research Projects

ASIF is growing its reputation and capacity to be involved in global research projects, by industry partners and by ASAS (an international group of experts in the field of spondyloarthritis).

ASIF supported a survey on the ASAS Quality Standards, which was led by an independent research agency on behalf of AbbVie. ASIF's Project Manager worked with the agency to co-create patient advertising materials and worked with patient organisations in 24 countries to disseminate the survey.

ASAS projects that ASIF took part in, include: PRAXIS for which ASIF recruited patients to complete a patient version of a survey for a study that seeks to formulate recommendations for the assessment of axSpA in daily clinical practice. ASIF provided PRPs for the working group that in 2025 published a new international definition of difficult-to-manage (D2M) axSpA. The aim was to create a shared definition so that patients, clinicians, researchers and advocacy groups can better identify unmet needs and improve care.

Global Remission Coalition

ASIF was delighted to be one of the founding members of the Global Remission Coalition that was launched on 21 May 2025 on the side of the World Health Assembly in Geneva, Switzerland. The main aim of the coalition will be to raise awareness about the value of remission and advocate for policies that prioritise the pursuit of remission.

Plans for 2026

ASIF's main areas of focus in 2026 will be:

ASIF Council Meeting
One of the key events for ASIF members, the Council Meeting in 2026 will be held in Athens in October. A main objective of the Council Meeting is to inspire members to grow the work they are doing and to strengthen their organisations. The theme of this Council Meeting is 'Collaboration'.

World AS Day
World AS Day will take place on 2 May 2026, with the theme 'Not only back pain'. Highlighting the comorbidities and Extra Musculoskeletal Manifestations that people living with axSpA experience. The campaign will raise awareness throughout April and May.

IMAP/EMAP
Work will continue to develop the study protocol, survey design and governance for the study. The study will be launched in Europe and fundraising will continue to secure finance for the global element of the study.

Financial review

Overview
During the year ASIF's total income was £257,243 (2024 - £329,517) of which £214,418 (2024 - £314,350) was grant income. Grant income includes £109,140 (2024 - £92,701) restricted to specific activities.

ASIF's total expenditure was £274,686 (2024 - £419,477) including £270,786 (2024 - £415,517) spent on charitable activities.

ASIF's income reduced in 2025 compared to previous years, largely due to the sudden loss of a major supporter. Some of that loss was offset by the contract work that was carried out in support of research. Staff have worked hard to forge new funding relationships and also by diversifying the work to include ASIF carrying out a major research study of its own, forecast income for 2026 is looking healthier.

Investment performance
ASIF's funds are held with HSBC and at CAF Bank. In 2025 Trustees approved the opening of a currency transfer account, Currencies Direct. That has now been opened and will create savings on international transactions. Trustees have approved that plans be made to close the HSBC accounts and transfer all holdings to CAF Bank.

Fundraising
ASIF does not seek to raise funds direct from the public; instead it solicits support from the

pharmaceutical industry and from associated institutions and charitable organisations.

Reserves
At the end of 2025 restricted funds carried forward totalled £87,201 (2024 - £17,050) and unrestricted funds carried forward totalled £125,350 (2024 - £212,944) which represents grant and sponsorship income from pharmaceutical partners for on-going projects.

Reserves are calculated on unrestricted funds, and at the year end were at 7 months which whilst at the lower end, is within the reserves policy.

The restricted funds are those amounts set aside to fund specific projects for which grants from pharmaceutical companies and other interested institutions are solicited. The unrestricted funds represent accumulated surplus income and unrestricted sponsorship funding and can be expended in accordance with ASIF's objectives without further restriction.

Statement of Trustees' responsibilities

The Trustees are responsible for preparing a Trustees' Annual Report and accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Trustees are required to prepare accounts for each financial year which give a true and fair view of the state of affairs of ASIF and of the incoming resources and application of funds for that year. In preparing those accounts, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the applicable accounting standards;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on a going concern basis unless it is inappropriate to presume that ASIF will continue in operation.

The Trustees are responsible for keeping proper accounting records that are sufficient to show and explain the transactions undertaken and to disclose with reasonable accuracy at any time the financial position of ASIF and to enable them to ensure that the accounts comply with relevant regulations and the provisions of the Constitution. They are also responsible for safeguarding the assets of ASIF and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the financial information included on ASIF's website. Legislation in the United Kingdom governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions.

Independent examiner

Axial Spondyloarthritis International Federation
Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation

Year ended 31 December 2025

John Gordon FCA is the charity's independent examiner.

The Trustees' Annual Report was approved on 18 May 2026 and signed on behalf of the board of Trustees by:

Nadia Malliou
Secretary

I report to the Trustees on my examination of the accounts of Axial Spondyloarthritis International Federation ('the charity') for the year ended 31 December 2025.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales (ICAEW), which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or

2. the accounts do not accord with those records; or

3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

John Gordon FCA
Independent Examiner

4 Bloomsbury Square
London
WC1A 2RP

18 May 2026

Axial Spondyloarthritis International Federation

Statement of Financial Activities

Year ended 31 December 2025

	Note	2025 Unrestricted funds £	2025 Restricted funds £	2025 **Total funds** £	2024 Total funds £
Incoming resources					
Donations and subscriptions	**5**	-	-	-	5,018
Grants received	**6**	105,278	109,140	214,418	314,350
Other	**7**	40,632	-	40,632	-
Investment income	**8**	2,193	-	2,193	10,149
Total incoming resources		148,103	109,140	257,243	329,517
Expenditure					
Expenditure on charitable activities		231,797	38,989	270,786	415,517
Governance costs	**9**	3,900	-	3,900	3,960
Total resources expended		235,697	38,989	274,686	419,477
Net movement in funds	**10**	87,594	70,151	(17,443)	(89,960)
Total funds brought forward		212,944	17,050	229,994	319,954
Total funds carried forward	**16**	125,350	87,201	212,551	229,994

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.

The notes on pages 11 to 18 form part of these accounts.

Axial Spondyloarthritis International Federation

Statement of Financial Position

31 December 2025

	Note	2025 £	2024 £
Current assets			
Debtors	**14**	123,979	17,050
Cash at bank and in hand		98,759	223,442
		222,738	240,492
Creditors: amounts falling due within one year	**15**	10,187	10,498
Total assets less current liabilities		212,551	229,994
Net assets		212,551	229,994
Funds of the charity			
Restricted funds		87,201	17,050
Unrestricted funds		125,350	212,944
Total charity funds	**16**	212,551	229,994

These accounts were approved by the board of Trustees and authorised for issue on 18 May 2026, and are signed on behalf of the board by:

Zhivko Yankov
Chairman

Nadia Malliou
Secretary

The notes on pages 11 to 18 form part of these accounts.

1. General information

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the registered office is 27 Old Gloucester Street, London, WC1N 3AX.

2. Statement of compliance

These accounts have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011.

3. Accounting policies

Basis of preparation

The accounts have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure.

The accounts are prepared in Sterling, which is the functional currency of the charity. Monetary amounts in these accounts are rounded to the nearest £1.

Going concern

There are no material uncertainties about the charity's ability to continue.

Judgements and key sources of estimation uncertainty

The preparation of the accounts requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the statement of financial activities.

Fund accounting

Restricted funds are maintained where the funds raised are to be used for specific purposes. Accumulated surplus income, which forms the Fund's reserves, is retained in unrestricted funds. Reserves are maintained to meet the Fund's continuing obligations and to cater for future needs and contingencies. Unrestricted funds comprise those funds which the Trustees are free to use for any purposes in furtherance of the charitable objects.

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- grants received from pharmaceutical companies towards shared costs are included in the Statement of Financial Activities when received or deferred to the extent that they relate to future accounting periods;

- income from donations is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably; and

- donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers.

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities; and

- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted.

Debt instruments are subsequently measured at amortised cost.

4. Transfer of funds

On 1 January 2024 the unrestricted and restricted funds in the charity Axial Spondyloarthritis International Federation (charity number 1173902) were transferred to Axial Spondyloarthritis International Federation (charity number 1205000).

5. Donations and subscriptions

	Unrestricted Funds £	**Total Funds 2025 £**	Unrestricted Funds £	Total Funds 2024 £
Donations				
Donations	-	-	1,219	1,219
Council meeting fees	-	-	3,799	3,799
	-	-	5,018	5,018

The charity no longer charges a subscription fee for membership.

6. Grants received

	Unrestricted Funds £	Restricted Funds £	**Total Funds 2025 £**
Pharma grants - unrestricted	105,278	-	105,278
Pharma grants - restricted	-	109,140	109,140
	105,278	109,140	214,418

6. Grants received (continued)

	Unrestricted Funds	Restricted Funds	Total Funds 2024
	£	£	£
Pharma grants - unrestricted	221,649	-	221,649
Pharma grants - restricted	-	92,701	92,701
	221,649	92,701	314,350

7. Other income

	Unrestricted Funds	**Total Funds 2025**	Unrestricted Funds	Total Funds 2024
	£	**£**	£	£
Contract work	40,632	40,632	-	-

8. Investment income

	Unrestricted Funds	**Total Funds 2025**	Unrestricted Funds	Total Funds 2024
	£	**£**	£	£
Bank interest receivable	2,193	2,193	10,149	10,149

9. Governance costs

	Unrestricted Funds	**Total Funds 2025**	Unrestricted Funds	Total Funds 2024
	£	**£**	£	£
Accountancy fees	2,400	2,400	2,400	2,400
Independent examination fees	1,500	1,500	1,560	1,560
	3,900	3,900	3,960	3,960

10. Net income

Net income is stated after charging:

	2025	2024
	£	£
Foreign exchange differences	551	5,730

11. Independent examination fees

	2025	2024
	£	£
Fees payable to the independent examiner for:		
Independent examination of the accounts	1,500	1,560

12. Staff costs

The average monthly number of employees (excluding trustees) during the year was:

	2025	2024
Administration and organisation	3	4

	Unrestricted Funds	**Total Funds 2025**	Unrestricted Funds	Total Funds 2024
	£	**£**	£	£
Wages and salaries	147,666	147,666	224,582	224,582
Social security costs	2,410	2,410	13,235	13,235
Other pension costs	6,446	6,446	10,145	10,145
	156,522	156,522	247,961	247,961

One employee earned between £60,000 and £70,000 per annum in respect of the year ended 31 December 2025 (2024 – one employee between £100,000 and £109,999).

13. Trustee remuneration and expenses

During the year ended 31 December 2025, six Trustees were reimbursed a total of £13,538 (2024 - £13,923) for expenses incurred including travel, accommodation and subsistence, in relation to the charity's activities.

14. Debtors

	2025	2024
	£	£
Other debtors	123,979	17,050
	123,979	17,050

15. Creditors: amounts falling due within one year

	2025	2024
	£	£
Social security and other taxes	5,783	1,766
Accruals and deferred income	4,404	8,732
	10,187	10,498

16. Analysis of charitable funds

Unrestricted funds

	At 1 January 2025	Income	Expenditure	Transfer (to) / from restricted funds	**At 31 December 2025**
	£	£	£	£	£
General funds	212,944	148,103	(235,697)	-	125,350

	At 1 January 2024	Income	Expenditure	Transfer (to) / from restricted funds	At 31 December 2024
	£	£	£	£	£
General funds	283,932	236,816	(143,599)	(164,205)	212,944

Unrestricted funds of £283,932 were transferred to charity 1205000 on 1 January 2024. Refer to note 4.

Restricted funds

	At 1 January 2025	Income	Expenditure	Transfer (to) / from unrestricted funds	**At 31 December 2025**
	£	£	£	£	£
World AS Day (WAS Day)	-	12,829	(12,829)	-	-
International Map of Axial Spondyloarthritis (IMAS)	-	-	-	-	-
Delay to Diagnosis (D2D)	-	-	-	-	-
International Map of Axial Spondyloarthritis and Psoriatic Arthritis (IMAP)	-	87,758	(557)	-	87,201
Other	17,050	8,553	(25,603)	-	-
	17,050	109,140	(38,989)	-	87,201

16. Analysis of charitable funds (continued)

	At 1 January 2024 £	Income £	Expenditure £	Transfer (to) / from unrestricted funds £	At 31 December 2024 £
World AS Day (WAS Day)	-	-	(53,781)	53,781	-
International Map of Axial Spondyloarthritis (IMAS)	36,022	29,954	(94,249)	28,773	-
Delay to Diagnosis (D2D)	-	12,913	(28,798)	15,885	-
International Map of Axial Spondyloarthritis and Psoriatic Arthritis (IMAP)	-	-	-	-	-
Other	-	49,834	(99,050)	66,266	17,050
	36,022	92,701	(275,878)	164,205	17,050

Restricted funds of £36,022 were transferred to charity 1205000 on 1 January 2024. Refer to note 4.

International Map of Axial Spondyloarthritis (IMAS) and the International Map of Axial Spondyloarthritis and Psoriatic Arthritis (IMAP)

IMAS was a project managed by ASIF in partnership with Novartis and the University of Seville. IMAS. It wasa global survey which generates and disseminates evidence about how people with axSpA experience their disease physically, psychologically and socially.

As of 2 January 2024, the International Map of axSpA is owned solely by the Axial Spondyloarthritis International Federation following an in-kind donation of the project by Novartis Pharma AG.

The value of the assets received by ASIF cannot be reliably measured and therefore no value is assigned to them in these accounts.

In consultation with members, trustees and other stakeholders including representatives of the global axSpA research community, it was agreed that a new project. IMAP should be launched, which would learn from the limitations of the first project IMAS. IMAP will start to collect data in 2027.

Delay to Diagnosis (D2D)

The objectives of this project are to significantly reduce the average time to diagnosis internationally; and to globally raise awareness about the disease and the detrimental effects of the delay, physically, psychologically and economically. In 2021 we produced a Global Burden Statement and built awareness and advocacy tools for our members.

Other
This includes Development of a psychosocial network for members and World AS Day.

17. Analysis of net assets between funds

	Unrestricted Funds £	Restricted Funds £	**Total Funds 2025 £**
Current assets	135,537	87,201	222,738
Creditors less than 1 year	(10,187)	-	(10,187)
Net assets	125,350	87,201	212,551

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Current assets	223,442	17,050	240,492
Creditors less than 1 year	(10,498)	–	(10,498)
Net assets	212,944	17,050	229,994